Insider Transactions Reported by 29 Insiders of Jade Biosciences, Inc.

Symbol
JBIO on Nasdaq
Location
Waltham, MA

Insiders trading volume in the past year

Jade Biosciences, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Sofinnova Venture Partners X, L.P. 10%+ Owner $73,294,377 02 Jul 2021
David S. Grayzel Director $50,853,006 05 Jun 2024
Fairmount Funds Management LLC Director, 10%+ Owner $48,084,557 06 Oct 2025
Atlas Venture Fund XII, L.P. 10%+ Owner $45,394,226 15 Jul 2022
Cormorant Asset Management, LP Former 10% Owner $39,598,475 02 Jul 2021
Timothy P. Noyes CHIEF EXECUTIVE OFFICER, Director $5,621,147 16 May 2024
Andrew James King Chief Scientific Officer & Head of Research and Development $5,351,526 12 Feb 2026
RA CAPITAL MANAGEMENT, L.P. 10%+ Owner $3,437,148 28 Apr 2025
Hunter Gillies Chief Medical Officer $1,504,308 13 Jun 2024
Tom Frohlich Chief Executive Officer, Director $1,196,547 +$44,400 +3.9% 12 Feb 2026
Marinus Verwijs Chief Technical Officer $1,126,256 14 Jun 2024
Timothy Pigot Chief Commercial Officer $923,420 22 Jan 2024
George A. Eldridge Officer Title: Chief Financial Officer and Treasurer $596,551 14 Jun 2024
Ralph Niven Chief Scientific Officer $591,035 05 Feb 2024
Bradford D. Dahms Chief Financial Officer $524,088 12 Feb 2026
Elizabeth Balta Chief Legal Officer and Corporate Secretary $389,812 12 Feb 2026
Lawrence Otto Klein Director $229,331 29 Apr 2025
Maha Katabi Director, 10%+ Owner $204,625 05 Jun 2024
Allison Dorval Director $204,625 05 Jun 2024
Iwicki Mark T. Director $204,625 05 Jun 2024
Habib J. Dable Director $204,625 05 Jun 2024
Joshua Resnick Director $204,625 05 Jun 2024
Donald J. Santel Director $204,625 05 Jun 2024
Dake Benjamin T. Officer Title: President, Chief Operating Officer and Secretary $24,798 31 Jul 2024
Erin Lavelle Director 29 Apr 2025
Eric Dobmeier Director 29 Apr 2025
Hetal Kocinsky Chief Medical Officer 28 Apr 2025
Christopher W. Cain Director 29 Apr 2025
Jonathan Quick Exhibit 24 - Power of Attorney Senior Vice President, Finance and Treasurer 28 Apr 2025

Recent Insider Transactions by Companies or Individuals for Jade Biosciences, Inc.

Showing up to 300 most recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
Bradford D. Dahms JBIO Common Stock Award 37,813 37,813 12 Feb 2026 Direct
Bradford D. Dahms JBIO Stock Option (Right to Buy) Award 226,875 226,875 12 Feb 2026 Direct
Elizabeth Balta JBIO Common Stock Award 28,125 28,125 12 Feb 2026 Direct
Elizabeth Balta JBIO Stock Option (Right to Buy) Award 168,750 168,750 12 Feb 2026 Direct
Tom Frohlich JBIO Common Stock Award 1038.8% 78,750 86,331 12 Feb 2026 Direct
Tom Frohlich JBIO Stock Option (Right to Buy) Award 472,500 472,500 12 Feb 2026 Direct
Andrew James King JBIO Common Stock Award 12% 41,250 386,113 12 Feb 2026 Direct
Andrew James King JBIO Stock Option (Right to Buy) Award 247,500 247,500 12 Feb 2026 Direct
Fairmount Funds Management LLC JBIO Common Stock Award 236.1% 1,333,126 1,897,677 06 Oct 2025 By Fairmount Healthcare Fund II L.P.
Fairmount Funds Management LLC JBIO Pre-Funded Warrant (Right to Buy) Award 855,047 855,047 06 Oct 2025 By Fairmount Healthcare Fund II L.P.
Bradford D. Dahms JBIO Stock Option (Right to Buy) Award 526,000 526,000 14 Jul 2025 Direct
Tom Frohlich JBIO Common Stock Purchase $44,400 $7.40 6,000 6,000 16 May 2025 Direct
Fairmount Funds Management LLC JBIO Stock Option (Right to Buy) Award 23,017 23,017 29 Apr 2025 Direct
Erin Lavelle JBIO Stock Option (Right to Buy) Award 23,017 23,017 29 Apr 2025 Direct
Lawrence Otto Klein JBIO Stock Option (Right to Buy) Award 23,017 23,017 29 Apr 2025 Direct
Christopher W. Cain JBIO Stock Option (Right to Buy) Award 23,017 23,017 29 Apr 2025 Direct
Eric Dobmeier JBIO Stock Option (Right to Buy) Award 23,017 23,017 29 Apr 2025 Direct
Ra Capital Management, L.P. JBIO Common Stock Other 471% 1,062,326 1,287,858 28 Apr 2025 See footnotes
* An asterisk sign (*) next to the price indicates that the price is likely invalid.